CJC-1295 and Ipamorelin: GH Secretagogue Stack Research Guide

CJC-1295 and Ipamorelin are two peptides that stimulate growth hormone (GH) release through distinct but complementary receptor mechanisms. CJC-1295 is a modified growth hormone-releasing hormone (GHRH) analogue acting on the GHRH receptor (GHRHR) in the anterior pituitary, while Ipamorelin is a ghrelin mimetic acting on the GH secretagogue receptor (GHS-R1a).

Their combination is studied because the two pathways are synergistic: GHRH receptor activation amplifies the amplitude of GH pulses, while GHS-R1a activation stimulates GH release independently. When combined, the two compounds produce a stronger GH release than either alone — a property explored extensively in the GH axis research literature.

CJC-1295 is a 30-amino-acid GHRH analogue (molecular weight ~3.3 kDa) incorporating modifications that extend its half-life relative to native GHRH(1-44). The version used in research blends is typically the DAC-free form (also called CJC-1295 without DAC or Mod GRF 1-29), which has a shorter half-life (~30 minutes) producing more physiological GH pulse patterns.

Key properties of CJC-1295 in research:

• Binds GHRH receptors in the pituitary to stimulate GH synthesis and secretion
• Increases both the amplitude and duration of GH pulses in a dose-dependent manner
• Does not significantly affect cortisol, prolactin, or ACTH at standard research doses
• Downstream effects on IGF-1 production are studied as a marker of GH axis activation

Ipamorelin is a synthetic cyclic pentapeptide (molecular weight ~711 Da) and selective GH secretagogue receptor (GHS-R1a) agonist. It was developed as an improvement on earlier ghrelin mimetics (GHRP-6, GHRP-2) due to its high selectivity for GHS-R1a without significant stimulation of ACTH, cortisol, or prolactin secretion.

Ipamorelin's selectivity makes it particularly useful in research studies requiring isolated GH axis stimulation. Its effects in research models include:

• Stimulation of GH release from anterior pituitary somatotrophs via GHS-R1a activation
• Ghrelin-like appetite signalling (GHS-R1a is also expressed in hypothalamic feeding circuits)
• Minimal effect on cortisol and prolactin compared to non-selective GH secretagogues

The combination of a GHRH analogue and a ghrelin mimetic produces a synergistic GH release response in multiple animal and human studies. The mechanism is well-understood: GHRH receptor activation primes somatotrophs for GH release, while GHS-R1a activation provides an independent stimulatory signal. When both pathways are activated simultaneously, GH release is substantially greater than additive.

This synergy is the basis for the combination's use in research protocols studying GH pulse physiology, IGF-1 axis modulation, and the neuroendocrine regulation of growth hormone.

RetaLABS CJC-1295 + Ipamorelin is supplied as a lyophilised blend. Recommended reconstitution:

• Add bacteriostatic water slowly along the vial wall and gently swirl until dissolved
• Store lyophilised vials at −20°C, protected from light
• Reconstituted solution: refrigerate at 2–8°C, use within 4 weeks
• Avoid repeated freeze-thaw cycles

See the Peptide Reconstitution Guide for detailed protocol notes. The CJC-1295 + Ipamorelin 10mg vial is available for research use. All products are supplied for laboratory research use only.